

Saskatchewan Health Authority - Saskatoon Area - ANTIBIOGRAM 2019
Adult Inpatients - NON-Urinary Isolates
January 1, 2019 - December 31, 2019

Inpatients – % Susceptible

# Isolates tested	Penicillin PO/IV	Penicillin - Meningitis	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftriaxone - Meningitis	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Azithromycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Gentamicin	Tobramycin	Vancomycin
GRAM-NEGATIVE BACTERIA																								
<i>Escherichia coli</i> ¹ -	204		47		69	95	R	88		80		80	100	100				69	59		69	90	82	
<i>Enterobacter aerogenes</i> ² † -	16		R		R	R	R	R		R		71	100	100				82	87		93	100	100	
<i>Enterobacter cloacae</i> ² -	55		R		R	R	R	R		R		71	96	82					95		89	100	100	
<i>Haemophilus influenzae</i> -	67		61						88	99			100			100				100	75			
<i>Klebsiella pneumoniae</i> ¹ -	87		98		92	99	50	92		95		95	100	100				82	89		91	94	93	
<i>Klebsiella oxytoca</i> † -	24		R		96	96	R	100		96		100	100	100					96		100	100	100	
<i>Pseudomonas aeruginosa</i> -	175					93						90	91						80			86	95	
<i>Morganella morganii</i> ² † -	15		R		R	R		R		R		93	100	100					73		73	87	100	
<i>Proteus mirabilis</i> † -	24		88		92	100		100		96		96	100	100					92		88	88	100	
<i>Stenotrophomonas maltophilia</i> † -	16											31									94			

# Isolates tested	Penicillin PO/IV	Penicillin - Meningitis	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftriaxone - Meningitis	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Azithromycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Gentamicin	Tobramycin	Vancomycin
GRAM-POSITIVE BACTERIA																								
<i>Staphylococcus aureus</i> , all																								
- methicillin-susceptible (MSSA) -	371			100			100								83		81	98	95	95	95			100
- methicillin-resistant (MRSA) -	244	R	R	R	R	R	R	R	R	R		R	R	R	59		35	100	52	53	94			100
<i>Staphylococcus epidermidis</i> -	135			R											46		R	89	49	49	48			100
<i>Staphylococcus lugdunensis</i> † -	27			93											74		78	100	96	96	100			100
<i>Streptococcus pneumoniae</i> -	86	100	86						94	100	99				89		78			100				100
Viridans group streptococci † -	23	48								91					87									100
<i>Streptococcus anginosus</i> group ³ -	45	100								100					84		80							100
Group A Streptococcus -	81	100	100							100					83		85							100
Group B Streptococcus -	38	100								100					47		50							100
Group C/G Streptococcus † -	16	100								100					88		75							100
<i>Enterococcus faecalis</i> ⁴ -	115		100				R	R	R	R	R	R			R		R	R	81	82				100
<i>Enterococcus faecium</i> ⁴ -	90		R				R	R	R	R	R	R			R		R	71	R	R				72

R - intrinsically resistant

† Isolates containing less than 30 reported specimens should be interpreted using presented data ALONG WITH clinical judgement and/or input from infectious diseases service

¹ Overall extended spectrum beta-lactamase (ESBL) activity was seen in a weighted average of 14.3 % of samples of *E.coli*, *K.pneumoniae* and *P.mirabilis*

²these organisms may produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility

³Streptococcus anginosus group includes: *S. anginosus*, *S. constellatus*, *S. intermedius*

⁴VRE (vancomycin-resistant Enterococci) isolated from clinical specimens: *E.faecium* 29% (N = 25)